Publication number: 20210386727
Abstract: The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3-{5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4] oxadiazol-2-yl}-1H-indazole (Compound-1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment, and behavioral and psychological symptoms of dementia such as apathy/indifference, agitation, aggression, depression, anxiety, irritability/lability, dysphoria, aberrant motor behavior, delusions, hallucinations, elation/euphoria, psychosis, disinhibition, sleep and night time behavior disorders or appetite and eating disorders. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.
Type:
Application
Filed:
October 17, 2019
Publication date:
December 16, 2021
Applicant:
SUVEN LIFE SCIENCES LIMITED
Inventors:
Ramakrishna NIROGI, Abdul Rasheed MOHAMMED, Anil Karbhari SHINDE, Venkata Ramalingayya GRANDHI, Pradeep JAYARAJAN, Vijay BENADE, Gopinadh BHYRAPUNENI, Venkateswarlu JASTI